Amedica Corporation Files for Initial Public Offering

    SALT LAKE CITY, May 22 /PRNewswire/ -- Amedica Corporation today
 announced that it has filed a registration statement with the Securities
 and Exchange Commission (SEC) on Form S-1 for the proposed initial public
 offering of its common stock. All the offered shares will be sold by the
 Company. Amedica plans to list its common stock on the NASDAQ Global Market
 under the symbol AMCA.
     Morgan Stanley & Co. Incorporated will act as sole bookrunning manager
 for the offering. Jefferies & Company, Inc. and CIBC World Markets Corp.
 will act as co-lead managers. When available, prospectuses may be obtained
 by contacting Morgan Stanley & Co. Incorporated, 180 Varick Street, 2nd
 Floor, New York, New York 10014, attention: Prospectus Department,
 866-718-1649, or by e-mailing prospectus@morganstanley.com.
     A registration statement relating to these securities has been filed
 with the SEC but has not yet become effective. These securities may not be
 sold, nor may offers to buy be accepted, prior to the time the registration
 statement becomes effective. This press release shall not constitute an
 offer to sell, or the solicitation of an offer to buy, nor shall there be
 any sale of these securities in any state or jurisdiction in which such
 offer, solicitation or sale would be unlawful prior to their registration
 or qualification under the securities laws of any such state or
 jurisdiction.
     About Amedica Corporation
     Amedica Corporation is an orthopedic implants company focused on using
 its silicon nitride ceramic technologies to develop, manufacture and
 commercialize a broad range of advanced, high-performance spine and joint
 implants.
 
 

SOURCE Amedica Corporation

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.